To evaluate the ability of the newly developed gene therapy protocol to confer protection against pathogens in vivo, p47phox-null mice  reconstituted with lentivirus-transduced cells were challenged with Salmonella Typhimurium (one of the major threats for CGD patients in developing countries and the leading cause of septicaemia in a European cohort [19]) and showed that the infection burden is significantly reduced, although not completely eradicated, after gene therapy. The gene discussed is NCF1; the disease is Sepsis.